Literature DB >> 25091374

Interference of cationic polymeric nanoparticles with clinical chemistry tests--clinical relevance.

Dzmitry Shcharbin1, Natallia Shcharbina2, Katarzyna Milowska3, Francisco Javier de la Mata4, Maria Angeles Muñoz-Fernandez5, Serge Mignani6, Rafael Gomez-Ramirez4, Jean-Pierre Majoral7, Maria Bryszewska3.   

Abstract

The development of medical nanosystems requires knowledge of their behavior in vivo. Clinical chemistry tests are widely used to estimate the systemic toxicity of nanoparticles. In this paper we have explored the impact of small positively charged nanoparticles-poly(amidoamine), phosphorous and carbosilane dendrimers - on biochemical parameters of standardized serum in vitro. All the dendrimers could shift the main biochemical parameters. Thus, in the case of patients having the normal, but 'boundary', values of biochemical parameters, nanoparticle-induced changes can be wrongly interpreted as evidence of some dysfunctions (hepatic, renal, etc.). Moreover, the effects of nanoparticles of metals, carbon nanotubes, quantum dots, fullerenes, dendrimers having been sized up to 4000 nm and the hundreds of reactive groups, can be significantly higher. Thus, preliminary evaluation of any nanomaterial in vitro is required in clinical chemistry tests before its application in vivo to draw the correct conclusions and benefit animals.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical chemistry test; Dendrimer; Enzyme; Nanoparticle; Protein

Mesh:

Substances:

Year:  2014        PMID: 25091374     DOI: 10.1016/j.ijpharm.2014.07.054

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Angiogenesis and proliferation of bile duct enhances ischemic tolerance in rats with cirrhosis.

Authors:  Zhiqiang Zhang; Zhennan Li; Chen Zou; Jingjing Zhang; Yi Zhu; Yi Miao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 2.  Which Dendrimer to Attain the Desired Properties? Focus on Phosphorhydrazone Dendrimers.

Authors:  Anne-Marie Caminade; Jean-Pierre Majoral
Journal:  Molecules       Date:  2018-03-09       Impact factor: 4.411

3.  In Vitro Anticancer Properties of Copper Metallodendrimers.

Authors:  Marcin Hołota; Jakub Magiera; Sylwia Michlewska; Małgorzata Kubczak; Natalia Sanz Del Olmo; Sandra García-Gallego; Paula Ortega; F Javier de la Mata; Maksim Ionov; Maria Bryszewska
Journal:  Biomolecules       Date:  2019-04-18

4.  Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.

Authors:  Sylwia Michlewska; Małgorzata Kubczak; Marta Maroto-Díaz; Natalia Sanz Del Olmo; Paula Ortega; Dzmitry Shcharbin; Rafael Gomez Ramirez; Francisco Javier de la Mata; Maksim Ionov; Maria Bryszewska
Journal:  Biomolecules       Date:  2019-08-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.